SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical
Incyte (INCY)
An SI Board Since January 1996
Posts SubjectMarks Bans Symbol
3202 131 0 INCY
Emcee:  scaram(o)uche Type:  Unmoderated
Introduction Market Data Compact
Previous 25 | Next 25 | View Recent | Post Message
Go to reply# or date (mm/dd/yy):
ReplyMessage PreviewFromRecsPosted
2677I am completely out of my INCY holdings based in part on this rebound effect newBiotech Jim-10/13/2011
2676This must be a different population of some sort given the dose was higher whileBiomaven-10/13/2011
2675Peter, Thanks for posting the news from the NEJM. FWIW, I also sold my holdingsoftware salesperson-10/13/2011
2674In today's NEJM, there is a letter reflecting a "sponsor-independent anBiomaven-10/12/2011
2673Leukemia. 2011 Sep 16. doi: 10.1038/leu.2011.255. [Epub ahead of print] Kinasescaram(o)uche-9/25/2011
2672Part of the reason, IMO, is YMI’s history of failure at every turn.DewDiligence_on_SI-9/23/2011
2671from YMI's fiscal 2011 results, out today..... <i>Subsequent to the scaram(o)uche-9/23/2011
2670Here comes Vertex's JAK3 for RA - results look very good at 12 weeks (seems Biomaven-9/7/2011
2669JAK1 in cancer: <i>ROCK and JAK1 Signaling Cooperate to Control ActomyosiBiomaven-8/15/2011
2668spittoon.23andme.com 23 and me launches MPN community software salesperson-8/3/2011
26677/28/11 cc notes 1. Opening remarks Rux NDA submitted 6/3; has versoftware salesperson27/28/2011
2666re. 050...... clinicaltrials.gov <i>The purpose of this trial is to assescaram(o)uche-7/20/2011
2665The anemia and efficacy data from this YMI poster looks pretty good: ymbioscienBiomaven-6/13/2011
2664This was the first mention of the diminishing nature of the red cell loss as farBiotech Jim-6/13/2011
2663Was the diminsishing nature of the anemia mentioned before? "ThrombocytopeD.Lu-6/12/2011
2662INCY reports further QOL data in myelofibrosis patients from COMFORT1 at the 16tBiotech Jim-6/12/2011
2661Incyte Announces Ruxolitinib (INC424) Shows Significant Clinical Benefit for Myetnsaf-6/6/2011
2660A surprise to me, incy is "hard to borrow" at my broker. edit: YMI, scaram(o)uche-6/3/2011
2659>>If they showed a survival benefit (which would be the first ever in thisBiomaven-5/11/2011
2658>>potentially be a registrational trial Well at that point the drug wouldBiomaven-5/11/2011
2657Thanks, SS. I was surprised to hear Friedman say that this could potentially bequantman-5/11/2011
2656from 5/10 BofA presentation rationale for rux pancreatic cancer trial: 1) animsoftware salesperson-5/11/2011
2655<i>So what is the reason for the apparent differential activity? </i>Biomaven-5/5/2011
2654>Found a low affinity MAb, and you can imagine how that impressed me.< Itformer_pgs-5/4/2011
2653Yeah.... I heard the anemia chatter, and went to the YM website to look at pscaram(o)uche-5/4/2011
Previous 25 | Next 25 | View Recent | Post Message
Go to reply# or date (mm/dd/yy):
HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2026 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News